Entera Bio(US:ENTX)2024-05-10 20:10Financial Position - As of March 31, 2024, Entera Bio had cash and cash equivalents of $9.2 million, sufficient to meet projected operating requirements into Q3 2025[9]. - Entera's total assets decreased to $10.2 million as of March 31, 2024, from $11.8 million as of December 31, 2023[17]. Expenses - Research and development expenses for Q1 2024 were $0.7 million, a decrease from $0.9 million in Q1 2023[10]. - General and administrative expenses remained stable at $1.3 million for both Q1 2024 and Q1 2023[10]. - Total operating expenses for Q1 2024 were $2.1 million, down from $2.2 million in Q1 2023[11]. Net Loss - The net loss for Q1 2024 was $2.0 million, or $0.05 per ordinary share, compared to a net loss of $2.2 million, or $0.08 per ordinary share, in Q1 2023[11]. Product Development - Entera is developing EB613, the first oral PTH(1-34) osteoanabolic tablet for osteoporosis, with a Phase 2 study showing positive results[12]. - The FDA is expected to rule on qualifying bone mineral density as a surrogate endpoint for fractures within 10 months, which could initiate EB613's pivotal Phase 3 study[6]. - Entera's collaboration with OPKO Health aims to develop oral GLP-2 tablets, which showed plasma levels approximately 10-fold higher than therapeutic concentrations for existing treatments[5]. - The company is also working on the first oral GLP-1/glucagon agonist peptide tablets for obesity, with pharmacokinetic data expected in mid-2024[7].